Fairfield, Bush & Co. Regeneron Pharmaceuticals, Inc. Transaction History
Fairfield, Bush & Co.
- $169 Billion
- Q1 2024
A detailed history of Fairfield, Bush & Co. transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Fairfield, Bush & Co. holds 1,982 shares of REGN stock, worth $2.09 Million. This represents 1.13% of its overall portfolio holdings.
Number of Shares
1,982
Previous 2,058
3.69%
Holding current value
$2.09 Million
Previous $1.81 Billion
5.54%
% of portfolio
1.13%
Previous 1.06%
Shares
18 transactions
Others Institutions Holding REGN
# of Institutions
1,427Shares Held
82.1MCall Options Held
835KPut Options Held
1.46M-
Vanguard Group Inc Valley Forge, PA8.93MShares$9.4 Billion0.17% of portfolio
-
Black Rock Inc. New York, NY8.57MShares$9.02 Billion0.19% of portfolio
-
Jpmorgan Chase & CO New York, NY7.73MShares$8.13 Billion0.68% of portfolio
-
State Street Corp Boston, MA4.84MShares$5.09 Billion0.21% of portfolio
-
Capital World Investors Los Angeles, CA4.65MShares$4.9 Billion0.76% of portfolio
About REGENERON PHARMACEUTICALS, INC.
- Ticker REGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 107,190,000
- Market Cap $113B
- Description
- Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...